Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's product pipeline... Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's product pipeline includes pepinemab (VX15), which targets Huntington's Disease (HD) and non-small cell lung cancer (NSCLC) and also neurodegenerative disorders; VX5 Autoimmune for the treatment of MS and potentially for other autoimmune disorder; and others. 詳細を表示
Actively Exploring Partnership for Alzheimer’s DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a...
ROCHESTER, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
ROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
ROCHESTER, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.436 | 11.6764863417 | 3.734 | 4.73 | 3.61 | 123902 | 4.27014011 | CS |
4 | 0.81 | 24.1071428571 | 3.36 | 4.73 | 2.8746 | 79706 | 3.68853055 | CS |
12 | -1.5799 | -27.4769996 | 5.7499 | 6 | 1.39 | 110838 | 3.13255874 | CS |
26 | -3 | -41.8410041841 | 7.17 | 8.9 | 1.39 | 90311 | 4.35781679 | CS |
52 | -6.302 | -60.179526356 | 10.472 | 13.02 | 1.39 | 73352 | 6.21993791 | CS |
156 | -291.93 | -98.5916919959 | 296.1 | 478.8 | 1.39 | 288554 | 149.6727693 | CS |
260 | -1039.53 | -99.6004599023 | 1043.7 | 2568.3 | 1.39 | 582377 | 674.08793946 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約